US › Healthcare

Perspective Therapeutics Inc. (CATX)

US · Healthcare · Medical Devices

$2.88+6.67%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$81,000

Revenue YoY

-72.1%

Net profit

$-26.8M

EPS

$-0.22

EPS estimate

$-0.27

Net margin

-33,069.1%

EPS came in at -0.22 against a street estimate of -0.27 — a beat of 18.5%.

Key statistics

Market cap

$311.6M

Forward P/E

25.7

P/B

1.03

Book value

$2.84

EPS (TTM)

$-1.33

52-week high

$6.16

52-week low

$1.96

50-day MA

$3.09

200-day MA

$3.59

Beta

1.80

Analyst view

Analysts rate Perspective Therapeutics Inc. a strong buy (13 buy, 1 hold, 0 sell out of 14) with an average price target of $12.29.

Shareholding

Insiders

10.45%

Institutions

85.91%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Perspective Therapeutics Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.